This has sparked a new wave of research aimed at elucidating the precise mechanisms by which GIP agonism, in the context of GLP-1 receptor activation, overcomes the apparent GIP resistance seen in T2DM to produce these enhanced metabolic benefits. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.